OVERSEA CHINESE BANKING Corp Ltd Has $37.84 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

OVERSEA CHINESE BANKING Corp Ltd grew its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 283,175 shares of the life sciences company’s stock after buying an additional 16,055 shares during the quarter. Illumina makes up about 1.1% of OVERSEA CHINESE BANKING Corp Ltd’s investment portfolio, making the stock its 21st largest holding. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Illumina were worth $37,841,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. Versant Capital Management Inc raised its position in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC bought a new position in shares of Illumina during the 4th quarter valued at $32,000. Assetmark Inc. lifted its stake in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina in the 4th quarter valued at $45,000. Finally, TD Private Client Wealth LLC boosted its holdings in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Performance

ILMN opened at $85.16 on Wednesday. The stock’s 50 day simple moving average is $111.38 and its 200-day simple moving average is $129.20. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The stock has a market cap of $13.49 billion, a PE ratio of -11.09, a P/E/G ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on ILMN. HSBC cut Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target for the company. in a research report on Friday, February 28th. Robert W. Baird decreased their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, March 5th. Guggenheim dropped their price target on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Canaccord Genuity Group decreased their price objective on shares of Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, March 11th. Finally, Stephens reiterated an “overweight” rating and issued a $156.00 target price on shares of Illumina in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.